Amiodarone: What have we learned from clinical trials?

Clinical Cardiology

Volumn 23, Issue 2, 2000, Pages 73-82

  Naccarelli, Gerald V ^a   Wolbrette, Deborah L ^a   Dell'Orfano, Joseph T ^a   Patel, Hemantkumar M ^a   Luck, Jerry C ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Amiodarone; Clinical trials; Ventricular tachycardia

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENCAINIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEXILETINE; MORACIZINE; PROPAFENONE; QUINIDINE; SOTALOL;

CLINICAL RESEARCH; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DRUG EFFICACY; DRUG INDICATION; HEART DISEASE; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; LUNG TOXICITY; RECURRENT DISEASE; REVIEW; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL;

EID: 0033961296     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960230203     Document Type: Review

References (52)

1. Gilman JK, Jalal S, Naccarelli GV: Predicting and preventing sudden death from cardiac causes. Circulation 1994;90:1083-1092
2. Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: An overview of results from randomized controlled trials. J Am Med Assoc 1993; 270:1589-1595
3. Lau J, Antman EM, Jimenez-Silva J, Kupelnic B, Mosteller F, Chalmers TC: Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-254
4. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J: B-blockers and sudden cardiac death. Ann Intern Med 1995;123:358-367
5. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE: Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med 1996;335:1660-1667
6. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE, Weaver WD: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-1428
7. Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC: A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: From CAST to AVID and beyond. J Cardiovasc Electrophysiol 1998;9:864-891
8. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman PL, Greene HL, Huther ML, Richardson DW, and the CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788
9. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pin B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancer 1996;348:7-12
10. Impact Research Group: International mexiletine and placebo antiarrhythmic coronary trial I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984;4:1148-1163
11. Julian DC, Prescott RJ, Jackson FS, Szekely P: Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1: 1142-1147
12. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233
13. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-1718
14. Pfisterer ME, Kiowski W, Brunner H, Burckhardt D, Burkart F: Long-term benefit of 1 year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation 1993;87:309-311
15. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, Dyduszynski A, Maciejewewicz J, Zaleska T, Lazarczyk-Kedzia E, Motyka J, Paczkowska B, Sczaniecka O, Yusuf S: Effect of amiodarone on mortality after myocardial infarction: A double-blind placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-1062
16. Navarro-Lopez F, Cosin J, Marrugat J, Guindo J, Bayes de Luna A, for the SSSD Investigators: Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Am J Cardiol 1993;72:1243-1248
17. Julian DG, Camm AJ, Franglin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators: Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674
18. Cairns, JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-682
19. Sim I, McDonald KM, Lavori PW, Norbutas Cm, Hlatky MA: Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997;96:2823-2829
20. Amiodarone Trials Meta-Analysis Investigators: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350: 14317-1424
21. Ho K, Pinsky J, Kannel W, Levy D: The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22:6A-13A
22. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532
23. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, Saxon LA, Natterson PD, Steimle A, Walden JA, Tillisch JH: Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28:1458-1463
24. Cleland JGF, Dargie HJ, Findlay JN, Wilson JT: Clinical hemodynamic and antiarrhythmic effects of long-term treatment with amiodarone of patients in heart failure. Br Heart J 1987;57: 436-445
25. Cleland JGF, Dargie HJ, Ford I: Mortality in heart failure: Clinical variables of prognostic value. Br Heart J 1987;58:572-582
26. Nicklas JM, McKenna WJ, Stewart RA, Mickelson JK, Das SK, Schork MA, Krikler SJ, Quain LA, Morady F, Pitt B: Prospective double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991;122:1016-1021
27. Garguichevich JJ, Ramos JL, Gambarte A, Gentile A, Hauad S, Scapin O, Sirena J, Tibaldi M, Toplikar J: Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine pilot study of sudden death and amiodarone (EPAMSA). Am Heart J 1995;130:494-500
28. Doval HC, Nul DR, Grancelli HO, Perrone SV, Borman GR, Curiel R for Grupo de Estudio de la Sobrevida en la Insufidencia Cardiaca en Argentina (GESICA): Randomized Trial of Low-Dose Amiodarone in Severe Congestive Heart Failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493-498
29. Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, Dubner S, Scapin O, Perrone SV, for the GESICA-GEMA Investigators: Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. Circulation 1996;94:3198-3203
30. Nul DR, Doval HC, Grancelli HO, Varini SD, Soifer S, Perrone SV, Prieto N, Scapin O, on behalf of the GESICA-GEMA Investigators: Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997;29:1199-1205
31. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (CHF-STAT): Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia (CHF-STAT). N Engl J Med 1995;333:77-82
32. Singh SN, Fisher SG, Carson PE, Fletcher RD, for the CHF STAT Investigators: Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. J Am Coll Cardiol 1998;32:942-947
33. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN, for the Department of Veterans Affairs CHF-STAT Investigators: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observations for the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 1998;98:2574-2579
34. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc 1995;273:1450-1456
35. Nisam S, Mower M: ICD trials: An extraordinary means of determining patient risk? PACE 1998;21:1341-1346
36. Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitsky LM, Multicenter Post-Infarction Research Group: The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the two years after myocardial infarction. Circulation 1984;69: 250-258
37. Wilber DJ, Olshansky B, Moran JF, Scanlon PJ: Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation 1990;82:350-358
38. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M, for the Multicenter Automatic Defibrillator Implantation Trial Investigators: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940
39. Buxton AE, Fisher JD, Josephson ME, Lee K, Pryor DB, Prystowsky EN, Simson MB, DiCarlo L, Echt DS, Packer D, Greer GS, Talajic M, The MUSTT Investigators: Prevention of sudden death in patients with coronary artery disease: The Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993; 36:215-226
40. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, Zou KH, Moss AJ: Cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Circulation 1998;97: 2129-2135
41. Buxton AE, Lee KL, DiCarlo L, Echt DS, Fisher JD, Greer GS, Josephson ME, Packer D, Prystowsky EN, Talajic M, for the Multicenter Unsustained Trial (MUSTT) Investigators: Nonsustained ventricular tachycardia in coronary artery disease: Relation to inducible sustained ventricular tachycardia. Ann Intern Med 1996; 125:35-39
42. The CASCADE Investigators: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-287
43. Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH, and the CASH Investigators: Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 1993;72:109F-113F
44. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583
45. Curtis AB, Hallstrom AF, Klein RC, Nath S, Pinski SL, Epstein AE, Wyse DG, Cannom DS, Renfroe E, for the AVID Investigators: Influence of patient characteristics in the selection of patients for defibrillator implantation (the AVID Registry). Am J Cardiol 1997;79:1185-1189
46. Kim SG, Hallstrom A, Love JC, Rosenberg Y, Powell J, Roth J, Brodsky M, Moore R, Wilkoff B, for the AVID Investigators: Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics Vs. Implantable Defibrillators (AVID) trial and nonrandomized registry patients. Am J Cardiol 1997;80:454-457
47. Anderson JL, Hallstrom AP, Epstein AE, Pinski SL, Rosenberg Y, Nora MO, Chilson D, Cannom DS, Moore R, and the AVID Investigators: Design and results of the Antiarrhythmics vs. Implantable Defibrillators (AVID) registry. Circulation 1999;99:1692-1699
48. Connolly S, Gent M, Roberts R, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D: Canadian Implantable Defibrillator Study (CIDS): Study design and organization. Am J Cardiol 1993;72:103F-108F
49. Wever EFD, Hauer RNW, van Capelle FJL, Tijssen JGP, Crijns HJGM, Algra A, Wiesfeld ACP, Bakker PFA, Robles de Medina EO: Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995;91:2195-2203
50. Naccarelli GV, Fineberg NS, Zipes DP, Heger JJ, Duncan G, Prystowsky EN: Amiodarone: Risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. J Am Coll Cardiol 1985;6:814-821
51. Myerburg RJ, Mitrani R, Interian A, Castellanos A: Interpretation of outcomes of antiarrhythmic clinical trials. Design features and population impact. Circulation 1998;97:1514-1521
52. Bigger JT, for the CABG Patch Trial Investigators: Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997;337:1569-1575